
A phase I study with 36 healthy subjects showed no significant drug–drug interaction between ZSP1273 (600 mg once daily) and oseltamivir (75 mg twice daily). The pharmacokinetic parameters for both drugs, including ZSP1273's Cmax,ss and AUC, were within the 80%–125% range. Oseltamivir’s Cmax,ss decreased by 39.9%, but the active metabolite showed no significant changes. Both therapies were well-tolerated with no increased safety risks.
Like
Save
Share